Receptor最新文献

Polyclonal antibodies from chickens and rabbits have been prepared against polypeptides representing two regions of the human estrogen receptor (hER). The estrogen receptor (ER) peptides used as antigens were overproduced in Escherichia coli. When indicated, the antibodies were affinity purified using resins to which the antigens contained in bacterial inclusion bodies had been coupled in high yield to epoxy-activated agarose. The antibodies recognize denatured human, bovine, rat, and rabbit ER in immunoblotting experiments. Immuno-precipitation of native ER protein was readily accomplished using rabbit antisera and immobilized protein A. The chicken antibodies, available in larger quantities, were also useful for immunoisolation after coupling to agarose. With the use of these reagents, the selective retrieval of chromatin fragments from MCF-7 cells that interact with ER has been achieved.

To further characterize the structure and regulation of the tyrosine kinase encoded by the rodent neu oncogene, its cytoplasmic tyrosine kinase domain has been expressed as a soluble protein, called Bacneu, in Sf9 insect cells, using the baculovirus expression system. Expression of Bacneu was detected by immunoblotting with anti p185neu antisera and in vitro autophosphorylation analysis as early as 24 h postinfection. Maximal expression was observed at 48 h postinfection. The soluble kinase was purified to near homogeneity by sequential chromatography on DEAE-Sepharose, phosphocellulose, poly-L-lysine, and Sephacryl 300, yielding 0.55 mg Bacneu per L of Sf9 cells (4% yield). The kinase is more active in the presence of Mn2+ compared to Mg2+ ions. The specific activity of the kinase using poly(Glu4Tyr1) as a substrate is 179 nmol/min/mg. Maximal incorporation of 1.4 mol of phosphate per mol of enzyme by autophosphorylation was found to increase the activity of the enzyme 1.5- to twofold. These results indicate that the Bacneu kinase is activated by phosphorylation. Therefore, it will be a useful reagent for characterizing the effects that phosphorylation by other cellular kinases and dephosphorylation by phosphatases have on its activity.

The IGF-1 receptor is expressed in many cell types, and its activation by its ligands is a required step for the proliferation of many cells in vivo and in vitro. In most cells in culture, requiring more than one growth factor for growth, the IGF-1 receptor can be found in one of two different modes: in the first mode, although it is autophosphorylated by its ligands and induces the expression of specific genes, it does not transmit a mitogenic signal. In the alternative mode, i.e., after priming with an unrelated growth factor, the IGF-1 receptor responds to its ligands with a mitogenic stimulus. This review examines briefly the possible alternatives to explain this different behavior, which is crucial to our understanding of the control of cellular proliferation.

In the present study, we have examined the relationship between estradiol (E2)-dependent regulation of estrogen receptor (ER) gene expression in normal mammary glands and its relationship to progesterone receptor (PgR) gene expression using tissues from E2-sensitive and -insensitive states. Estradiol caused a time-dependent decrease in ER mRNA levels in E2-sensitive mammary glands reaching a maximum at approx 6 h, at which time the levels of PgR mRNA also reached a maximum. In contrast, in E2-insensitive mammary glands, there was no E2-dependent decrease in ER mRNA at all times tested. Experiments using dissociated cells revealed that although the epithelial cells of mammary glands from both E2-sensitive and -insensitive states contained ER mRNA, in the intact E2-sensitive mammary glands, it was the nonepithelial ER that was decreasing in response to E2. Since the epithelial cells of normal mammary glands are the primary target for E2-dependent PgR synthesis, our studies suggest that a positive correlation between E2-dependent PgR gene expression and E2-dependent downregulation of ER may simply be coincidental and may not bear any true biological relationship.

Sulfhydryl groups were studied in opioid receptors solubilized from bovine striatal membranes and reconstituted into liposomes. This system has the advantage of permitting the complete uncoupling of tightly coupled opioid binding sites from guanine nucleotide binding proteins. Sensitivity of opioid receptors to N-ethylmaleimide (NEM) inactivation, as measured by [3H]bremazocine binding, was similar whether coupled or uncoupled from the G protein. Moreover, the binding of uncoupled receptors could be protected from NEM inactivation by preincubation with a ligand, as previously observed in coupled, membrane-bound receptors. These findings provide strong support of earlier results suggesting the presence of sulfhydryl groups on opioid binding sites. An examination of the major receptor types provided the following decreasing order of sensitivity to NEM: mu > delta > kappa. Mu agonist binding was found to be much more sensitive to NEM than antagonist binding, especially in the presence of NaCl, which affects the binding of the two types of ligands in opposite directions, as previously reported for membrane-bound receptors. At 100 microM NEM in the presence of 100 mM NaCl, [3H] (D-Ala2,N-methyl-Phe4,Gly-ol)-enkephalin (DAGO) binding is essentially eliminated, whereas [3H]bremazocine or [3H]naloxone binding is virtually unaffected. These results are most readily explained by the hypothesis that there are two sulfhydryl groups at or near the mu binding site; one essential for agonist (but not antagonist) binding, the other essential for antagonist and perhaps, also agonist binding. The sodium effect on NEM inactivation of antagonist binding was maintained in the uncoupled state indicating that this effect occurs at the level of the receptor protein.

We have characterized the binding of 125I-IGF-I and 125I-IGF-II to plasma membranes purified from human thyroid tissue. IGF binding was time- and temperature-dependent. At 4 degrees C, maximal specific binding of 125I-IGF-I was 17.3 +/- 2.5% and of 125I-IGF-II was 8.8 +/- 2.0% (mean +/- SD/60 micrograms membrane protein). 125I-IGF-I binding was inhibited completely by unlabeled IGF-I, IGF-II, insulin, and the type-I IGF receptor monoclonal antibody, alpha IR-3. 125I-IGF-II was inhibited completely by unlabeled IGF-II and nearly completely by IGF-I. 125I-IGF-II binding also was inhibited significantly by insulin, suggesting that much or all of the IGF-II was bound to the type-I IGF receptor. Scatchard analysis revealed a single class of binding sites with a Kd of 6.0 +/- 4.2 x 10(-10) M for IGF-I binding and 5.7 +/- 1.3 x 10(-10) M for IGF-II binding. IGF-I binding was inhibited by a variety of salts in a dose-dependent manner, calcium and magnesium salts being more effective than sodium or potassium salts. Affinity crosslinking of 125I-IGF-I and -II showed clear evidence only for type-I IGF receptors. Thus, a crude plasma membrane fraction of human thyroid tissue expresses predominantly type-I IGF receptors.

The purpose of these experiments was to label an alpha 2-adrenergic receptor ligand with a positron emitting isotope and then test this radioligand in vivo. No-carrier-added [11C]WY26703 was synthesized by methylation of its desmethyl precursor, WY27050 with [11C]H3I followed by purification with HPLC in 14% yield in a synthesis time of 35 min from EOB. Ki values for unlabeled WY26703, ranged from 0.52-1.55 nM in tissues that express a single alpha 2-adrenergic receptor subtype. Tail vein injections of [11C]WY26703 in mice revealed that the compound was distributed in the brain, heart, lungs, spleen, and kidneys. In the brains of rats treated with atipamezole, an alpha 2-adrenergic receptor antagonist, there was no decrease in [11C] accumulation indicating a lack of observable specific binding of the radioligand. When brain tissue was homogenized and filtered, however, atipamezole decreased [11C] activity by 53%. Therefore, [11C]WY26703 crosses the blood-brain barrier and specifically binds to alpha 2-adrenergic receptors with high affinity. Atipamezole treatment decreased only the area of the locus coeruleus [11C] value of the various regions of the brain. The affinity, however, of [11C]WY26703 does not appear to distinguish alpha 2-receptors from nonspecific binding sites. PET study of [11C]WY26703 in a Rhesus monkey showed that influx of [11C]WY26703 into the brain was high for the first few minutes but radioactivity then declined rapidly and did not retain in a specific brain region. This suggests that [11C]WY26703 may not be a useful ligand for imaging human alpha 2-adrenergic receptors by positron emission tomography.

In primary glial cultures, norepinephrine (NE) activates both beta-adrenergic receptors to increase cAMP formation and alpha 2-adrenergic receptors to partially inhibit this response. We used selective alkylating agents to compare the concentration-dependence and receptor reserves for activation of each subtype. Partial inactivation of beta-receptors with alkylating pindolol (BIM) caused a slight decrease in the potency of isoproterenol (ISO) in increasing cAMP accumulation and a progressive decrease in maximum response. The KA for ISO was 9.8 +/- 2 nM, with a 2-3-fold beta-receptor reserve. BIM pretreatment decreased the maximal response to NE without significantly altering its apparent EC50 (41 +/- 6.7 nM). Partial inactivation of alpha 2-adrenergic receptors with EEDQ increased the maximal response to NE without significantly altering its apparent EC50 (41 +/- 6.2 nM). NE inhibited the cAMP response to ISO with an apparent EC50 of 38 +/- 1.2 nM. EEDQ pretreatment reduced inhibition of the ISO response by both NE and the alpha 2-agonist UK 14,304, and inhibition of the forskolin response by UK 14,304. EEDQ pretreatment caused only a small decrease in potency for the alpha 2-agonists. The KA for NE in inhibiting the ISO response was 120 +/- 30 nM, indicating a 2-3-fold alpha 2-receptor reserve. These results suggest that NE has similar affinities and receptor reserves for beta- and alpha 2-adrenergic receptors in this system, and activates and inhibits adenylate cyclase at the same agonist concentrations.

A series of lipophilic benzophenone dicarboxylic acids have been shown to be inhibitors of the binding of LTB4 to its receptors on intact human neutrophils (Gapinski et al. (1990). Structure-activity relationships indicated that maximum activity was achieved when an acid group was attached at the meta position of each ring. In this report, the conformation of these inhibitors that binds best to the LTB4 receptor was determined. Inhibition concentration profiles of four rigid xanthone isomers that mimicked the four major conformational states of this type of benzophenone dicarboxylic acid were compared. LY264086, 3-[4-[7-carboxy-3-[decyloxy]-9-oxo-9H-xanthene]]propanoic acid, was the most potent inhibitor. The distance between the two carboxyl groups in this isomer was found to be 9.8 A, implying that the two acid binding sites on the receptor are separated by similar dimensions. Molecular modeling studies with low energy conformers of the xanthone isomers and LTB4 suggested a configuration of the agonist when it is bound to the receptor but did not exclude all other possibilities. These experiments further support the existence of two acid-binding sites on the human neutrophil LTB4 receptor.

The structures of the unactivated and activated mineralocorticoid receptors have been difficult to characterize because of receptor lability and steroid dissociation. Therefore, human mineralocorticoid receptor mRNA was translated in rabbit reticulocyte lysate in the presence and absence of [35S]methionine to compare the structure of [3H]aldosterone-bound and [35S]labeled receptor. In vitro synthesized receptor was able to specifically bind [3H]aldosterone. Unactivated [3H]aldosterone-bound and 60% of unactivated [35S]labeled receptor eluted from DEAE-cellulose with 250 mM salt and had a Rs of 72A. Forty percent of unactivated [35S]labeled receptor eluted from DEAE-cellulose with 100 mM salt and had a Rs of 54A. SDSPAGE showed intact hMR was present in both DEAE-cellulose eluates as three bands between M(r) 110,000-120,000. However, the low salt eluate contained less intact receptor and more lower MW bands. Neither [3H]aldosterone-bound nor [35S]labeled receptor was activated by incubation at 25 degrees C as readily as glucocorticoid receptor studied under identical conditions. Activated [3H]aldosterone-bound receptor eluted from DEAE-cellulose at 100 mM salt and had a Rs of 37A. After activation, 60% of [35S]labeled receptor eluted from DEAE-cellulose with 100 mM salt and had a Rs of 91A. SDS-PAGE of the high and low salt DEAE-cellulose eluates showed that 50% of intact receptor eluted in the low salt peak after activation. These data indicate that: 1. Some in vitro synthesized mineralocorticoid receptor assembles into the heteromeric unactivated form; 2. The remaining intact receptor remains monomeric and unable to bind steroid; 3. Activation causes dissociation of intact receptor from a larger complex; and 4. Activated receptor tends to aggregate.